There are 2949 resources available
1047P - Long terms efficacy of anti-PD(L)1 in MSI tumours
Presenter: Cristina Smolenschi
Session: E-Poster Display
Resources:
Abstract
1048P - Should I stay or should I go: Optimal duration for antiPD(L)1 therapy
Presenter: Jeanne Chen
Session: E-Poster Display
Resources:
Abstract
1049P - Efficacy and safety of low dose immunotherapy in palliative setting of advanced solid tumours
Presenter: Amit Kumar
Session: E-Poster Display
Resources:
Abstract
1050P - Does immunotherapy impact the outcomes of future anti-tumour therapies?
Presenter: Manuela Tiako Meyo
Session: E-Poster Display
Resources:
Abstract
1051P - Clinical experience of tabelecleucel in patients with EBV+ primary (PID) or acquired immunodeficiency (AID) associated lymphoproliferative disease
Presenter: Sarah Nikiforow
Session: E-Poster Display
Resources:
Abstract
1052P - Genetic modification of Iovance’s TIL through TALEN-mediated knockout of PD-1 as a strategy to empower TIL therapy for cancer
Presenter: Krit Ritthipichai
Session: E-Poster Display
Resources:
Abstract
1053P - Iovance generation-2 tumour-infiltrating lymphocyte (TIL) product is reinvigorated during the manufacturing process
Presenter: Michelle Simpson-Abelson
Session: E-Poster Display
Resources:
Abstract
1054P - Treatment history affects bone marrow toxicity after conditioning non-myeloablative chemotherapy in adoptive cell therapy in non-melanoma cancer patients
Presenter: Anders Kverneland
Session: E-Poster Display
Resources:
Abstract
1055P - Updated results of subcutaneous (SC) anti-programmed cell death 1 (PD-1) receptor antibody PF-06801591 for locally advanced or metastatic non-small cell lung cancer (NSCLC) or urothelial carcinoma (UC)
Presenter: Byong Chul Cho
Session: E-Poster Display
Resources:
Abstract
1056P - Durvalumab (D) in combination with chemoradiotherapy (CRT) in solid tumours: Phase I CLOVER study
Presenter: Julie Bauman
Session: E-Poster Display
Resources:
Abstract